Latest Paradigm Biocapital Advisors LP Stock Portfolio
Paradigm Biocapital Advisors LP Performance:
2025 Q3: 23.7%YTD: 4.77%2024: 10.07%
Performance for 2025 Q3 is 23.7%, and YTD is 4.77%, and 2024 is 10.07%.
About Paradigm Biocapital Advisors LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Paradigm Biocapital Advisors LP reported an equity portfolio of $3.5 Billions as of 30 Sep, 2025.
The top stock holdings of Paradigm Biocapital Advisors LP are NUVL, MRUS, ACLX. The fund has invested 13% of it's portfolio in NUVALENT INC and 11.7% of portfolio in MERUS N V.
The fund managers got completely rid off BEONE MEDICINES LTD (BGNE), MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and Y-MABS THERAPEUTICS INC (YMAB) stocks. They significantly reduced their stock positions in DISC MEDICINE INC, COGENT BIOSCIENCES INC (COGT) and BRIDGEBIO PHARMA INC (BBIO). Paradigm Biocapital Advisors LP opened new stock positions in ABIVAX SA, CIDARA THERAPEUTICS INC (CDTX) and UROGEN PHARMA LTD (URGN). The fund showed a lot of confidence in some stocks as they added substantially to AGIOS PHARMACEUTICALS INC (AGIO), PHARVARIS N V (PHVS) and APOGEE THERAPEUTICS INC.
The top stock holdings of Paradigm Biocapital Advisors LP are NUVL, MRUS, ACLX. The fund has invested 13% of it's portfolio in NUVALENT INC and 11.7% of portfolio in MERUS N V.
The fund managers got completely rid off BEONE MEDICINES LTD (BGNE), MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and Y-MABS THERAPEUTICS INC (YMAB) stocks. They significantly reduced their stock positions in DISC MEDICINE INC, COGENT BIOSCIENCES INC (COGT) and BRIDGEBIO PHARMA INC (BBIO). Paradigm Biocapital Advisors LP opened new stock positions in ABIVAX SA, CIDARA THERAPEUTICS INC (CDTX) and UROGEN PHARMA LTD (URGN). The fund showed a lot of confidence in some stocks as they added substantially to AGIOS PHARMACEUTICALS INC (AGIO), PHARVARIS N V (PHVS) and APOGEE THERAPEUTICS INC.
Paradigm Biocapital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Paradigm Biocapital Advisors LP made a return of 23.7% in the last quarter. In trailing 12 months, it's portfolio return was -2.33%.
New Buys
| Ticker | $ Bought |
|---|---|
| abivax sa | 132,800,000 |
| genmab a/s | 117,063,000 |
| cidara therapeutics inc | 92,041,100 |
| urogen pharma ltd | 84,110,900 |
| eyepoint pharmaceuticals inc | 28,556,400 |
| tango therapeutics inc | 25,923,900 |
| amylyx pharmaceuticals inc | 25,821,000 |
| dyne therapeutics inc | 24,021,700 |
New stocks bought by Paradigm Biocapital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| agios pharmaceuticals inc | 134 |
| pharvaris n v | 72.69 |
| apogee therapeutics inc | 58.74 |
| scholar rock hldg corp | 25.57 |
| alkermes plc | 24.99 |
| erasca inc | 13.88 |
| vaxcyte inc | 12.21 |
| crinetics pharmaceuticals in | 8.84 |
Additions to existing portfolio by Paradigm Biocapital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| disc medicine inc | -79.54 |
| cogent biosciences inc | -69.51 |
| lenz therapeutics inc | -37.48 |
| bridgebio pharma inc | -29.15 |
| spyre therapeutics inc | -21.56 |
| tarsus pharmaceuticals inc | -10.43 |
| viridian therapeutics inc | -4.82 |
Paradigm Biocapital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| y-mabs therapeutics inc | -19,105,900 |
| immatics n.v | -16,915,600 |
| moonlake immunotherapeutics | -41,456,800 |
| crescent biopharma inc. | -10,373,500 |
| beone medicines ltd | -84,188,800 |
Paradigm Biocapital Advisors LP got rid off the above stocks
Sector Distribution
Paradigm Biocapital Advisors LP has about 86.6% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 86.6 |
| Others | 13.4 |
Market Cap. Distribution
Paradigm Biocapital Advisors LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 61.3 |
| SMALL-CAP | 21.8 |
| UNALLOCATED | 13.4 |
| MICRO-CAP | 3.5 |
Stocks belong to which Index?
About 70.9% of the stocks held by Paradigm Biocapital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 70.9 |
| Others | 29.1 |
Paradigm Biocapital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Paradigm Biocapital Advisors LP
Paradigm Biocapital Advisors LP has 33 stocks in it's portfolio. About 65.4% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. MRUS was the most profitable stock for Paradigm Biocapital Advisors LP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 10.86 | 4,649,020 | 381,684,000 | unchanged | 0.00 | ||
| AGIO | agios pharmaceuticals inc | 3.05 | 2,673,560 | 107,316,000 | added | 134 | ||
| AGLE | spyre therapeutics inc | 0.70 | 1,467,270 | 24,591,400 | reduced | -21.56 | ||
| ALKS | alkermes plc | 1.47 | 1,719,330 | 51,580,000 | added | 24.99 | ||
| AMLX | amylyx pharmaceuticals inc | 0.73 | 1,900,000 | 25,821,000 | new | |||
| BBIO | bridgebio pharma inc | 1.01 | 684,277 | 35,541,300 | reduced | -29.15 | ||
| BGNE | beone medicines ltd | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CDTX | cidara therapeutics inc | 2.62 | 961,164 | 92,041,100 | new | |||
| COGT | cogent biosciences inc | 1.29 | 3,156,400 | 45,325,900 | reduced | -69.51 | ||
| CRNX | crinetics pharmaceuticals in | 3.02 | 2,550,770 | 106,240,000 | added | 8.84 | ||
| DYN | dyne therapeutics inc | 0.68 | 1,898,950 | 24,021,700 | new | |||
| ERAS | erasca inc | 0.84 | 13,560,000 | 29,560,800 | added | 13.88 | ||
| EWTX | edgewise therapeutics inc | 2.85 | 6,170,130 | 100,080,000 | added | 0.45 | ||
| EYPT | eyepoint pharmaceuticals inc | 0.81 | 2,005,360 | 28,556,400 | new | |||
| JANX | janux therapeutics inc | 2.03 | 2,920,260 | 71,371,100 | unchanged | 0.00 | ||
| MLTX | moonlake immunotherapeutics | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MRUS | merus n v | 11.71 | 4,373,770 | 411,790,000 | added | 2.14 | ||
| NUVL | nuvalent inc | 12.96 | 5,269,430 | 455,701,000 | unchanged | 0.00 | ||
| OCUL | ocular therapeutix inc | 1.16 | 3,497,310 | 40,883,500 | added | 2.25 | ||
| OLMA | olema pharmaceuticals inc | 1.89 | 6,794,170 | 66,514,900 | added | 0.44 | ||